APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metoclopramide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metoclopramide Market Outlook and Growth Opportunities 2026

19 December 2025213 pages

Choose your research edition.

Industry ResearchMetoclopramide Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Metoclopramide Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Metoclopramide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metoclopramide Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Metoclopramide Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Metoclopramide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metoclopramide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metoclopramide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metoclopramide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metoclopramide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metoclopramide market include Adwya, Alkaloid Pharmaceuticals, Amneal Pharmaceuticals, Apotex, ASKA Seiyaku Asuka, Astellas, Biofarma, Ceva Sante Animale and EU-Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metoclopramide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metoclopramide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metoclopramide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metoclopramide market size, projected growth trends, production technologies, key applications, and end-use industries.

Metoclopramide Segment by Company

Adwya

Alkaloid Pharmaceuticals

Amneal Pharmaceuticals

Apotex

ASKA Seiyaku Asuka

Astellas

Biofarma

Ceva Sante Animale

EU-Pharma

Le Vet

Meda Pharma

Nidda

Omega Laboratories

Orion Pharma

Teuto Brasileiro

Wockhardt

Yang Sheng

GSK

Pfizer

Mylan

Novartis

Johnson and Johnson

Sanofi

Teva

Metoclopramide Segment by Type

Oral

Injection

Metoclopramide Segment by Application

Nausea

Migraine

Gastroparesis

Metoclopramide Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Metoclopramide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metoclopramide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metoclopramide significant trends, drivers, influence factors in global and regions.

6. To analyze Metoclopramide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metoclopramide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metoclopramide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metoclopramide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metoclopramide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metoclopramide industry.

Chapter 3: Detailed analysis of Metoclopramide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metoclopramide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metoclopramide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metoclopramide Industry Trends Table 2. Metoclopramide Industry Drivers Table 3. Metoclopramide Industry Opportunities and Challenges Table 4. Metoclopramide Industry Restraints Table 5. Global Metoclopramide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metoclopramide Revenue Share by Company (2021-2026) Table 7. Global Metoclopramide Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Metoclopramide Sales Volume Share by Company (2021-2026) Table 9. Global Metoclopramide Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Metoclopramide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metoclopramide Key Company Manufacturing Base & Headquarters Table 12. Global Metoclopramide Company, Product Type & Application Table 13. Global Metoclopramide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metoclopramide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Global Metoclopramide Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Metoclopramide Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Metoclopramide Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Metoclopramide Sales Volume Share by Type (2021-2026) Table 23. Global Metoclopramide Sales Volume Share by Type (2027-2032) Table 24. Global Metoclopramide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Metoclopramide Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Metoclopramide Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Metoclopramide Sales Value Share by Type (2021-2026) Table 28. Global Metoclopramide Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Nausea Table 30. Significant Companies of Migraine Table 31. Significant Companies of Gastroparesis Table 32. Global Metoclopramide Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Metoclopramide Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Metoclopramide Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Metoclopramide Sales Volume Share by Application (2021-2026) Table 36. Global Metoclopramide Sales Volume Share by Application (2027-2032) Table 37. Global Metoclopramide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Metoclopramide Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Metoclopramide Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Metoclopramide Sales Value Share by Application (2021-2026) Table 41. Global Metoclopramide Sales Value Share by Application (2027-2032) Table 42. Global Metoclopramide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Metoclopramide Sales by Region (2021-2026) & (K Units) Table 44. Global Metoclopramide Sales Market Share by Region (2021-2026) Table 45. Global Metoclopramide Sales by Region (2027-2032) & (K Units) Table 46. Global Metoclopramide Sales Market Share by Region (2027-2032) Table 47. Global Metoclopramide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Metoclopramide Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Metoclopramide Sales Value Share by Region (2021-2026) Table 50. Global Metoclopramide Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Metoclopramide Sales Value Share by Region (2027-2032) Table 52. Global Metoclopramide Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Metoclopramide Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Metoclopramide Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Metoclopramide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Metoclopramide Sales by Country (2021-2026) & (K Units) Table 57. Global Metoclopramide Sales Market Share by Country (2021-2026) Table 58. Global Metoclopramide Sales by Country (2027-2032) & (K Units) Table 59. Global Metoclopramide Sales Market Share by Country (2027-2032) Table 60. Global Metoclopramide Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Metoclopramide Sales Value Market Share by Country (2021-2026) Table 62. Global Metoclopramide Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Metoclopramide Sales Value Market Share by Country (2027-2032) Table 64. Adwya Company Information Table 65. Adwya Business Overview Table 66. Adwya Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Adwya Metoclopramide Product Portfolio Table 68. Adwya Recent Development Table 69. Alkaloid Pharmaceuticals Company Information Table 70. Alkaloid Pharmaceuticals Business Overview Table 71. Alkaloid Pharmaceuticals Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Alkaloid Pharmaceuticals Metoclopramide Product Portfolio Table 73. Alkaloid Pharmaceuticals Recent Development Table 74. Amneal Pharmaceuticals Company Information Table 75. Amneal Pharmaceuticals Business Overview Table 76. Amneal Pharmaceuticals Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Amneal Pharmaceuticals Metoclopramide Product Portfolio Table 78. Amneal Pharmaceuticals Recent Development Table 79. Apotex Company Information Table 80. Apotex Business Overview Table 81. Apotex Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Apotex Metoclopramide Product Portfolio Table 83. Apotex Recent Development Table 84. ASKA Seiyaku Asuka Company Information Table 85. ASKA Seiyaku Asuka Business Overview Table 86. ASKA Seiyaku Asuka Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. ASKA Seiyaku Asuka Metoclopramide Product Portfolio Table 88. ASKA Seiyaku Asuka Recent Development Table 89. Astellas Company Information Table 90. Astellas Business Overview Table 91. Astellas Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Astellas Metoclopramide Product Portfolio Table 93. Astellas Recent Development Table 94. Biofarma Company Information Table 95. Biofarma Business Overview Table 96. Biofarma Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Biofarma Metoclopramide Product Portfolio Table 98. Biofarma Recent Development Table 99. Ceva Sante Animale Company Information Table 100. Ceva Sante Animale Business Overview Table 101. Ceva Sante Animale Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Ceva Sante Animale Metoclopramide Product Portfolio Table 103. Ceva Sante Animale Recent Development Table 104. EU-Pharma Company Information Table 105. EU-Pharma Business Overview Table 106. EU-Pharma Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. EU-Pharma Metoclopramide Product Portfolio Table 108. EU-Pharma Recent Development Table 109. Le Vet Company Information Table 110. Le Vet Business Overview Table 111. Le Vet Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Le Vet Metoclopramide Product Portfolio Table 113. Le Vet Recent Development Table 114. Meda Pharma Company Information Table 115. Meda Pharma Business Overview Table 116. Meda Pharma Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Meda Pharma Metoclopramide Product Portfolio Table 118. Meda Pharma Recent Development Table 119. Nidda Company Information Table 120. Nidda Business Overview Table 121. Nidda Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Nidda Metoclopramide Product Portfolio Table 123. Nidda Recent Development Table 124. Omega Laboratories Company Information Table 125. Omega Laboratories Business Overview Table 126. Omega Laboratories Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Omega Laboratories Metoclopramide Product Portfolio Table 128. Omega Laboratories Recent Development Table 129. Orion Pharma Company Information Table 130. Orion Pharma Business Overview Table 131. Orion Pharma Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Orion Pharma Metoclopramide Product Portfolio Table 133. Orion Pharma Recent Development Table 134. Teuto Brasileiro Company Information Table 135. Teuto Brasileiro Business Overview Table 136. Teuto Brasileiro Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Teuto Brasileiro Metoclopramide Product Portfolio Table 138. Teuto Brasileiro Recent Development Table 139. Wockhardt Company Information Table 140. Wockhardt Business Overview Table 141. Wockhardt Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Wockhardt Metoclopramide Product Portfolio Table 143. Wockhardt Recent Development Table 144. Yang Sheng Company Information Table 145. Yang Sheng Business Overview Table 146. Yang Sheng Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Yang Sheng Metoclopramide Product Portfolio Table 148. Yang Sheng Recent Development Table 149. GSK Company Information Table 150. GSK Business Overview Table 151. GSK Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. GSK Metoclopramide Product Portfolio Table 153. GSK Recent Development Table 154. Pfizer Company Information Table 155. Pfizer Business Overview Table 156. Pfizer Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Pfizer Metoclopramide Product Portfolio Table 158. Pfizer Recent Development Table 159. Mylan Company Information Table 160. Mylan Business Overview Table 161. Mylan Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Mylan Metoclopramide Product Portfolio Table 163. Mylan Recent Development Table 164. Novartis Company Information Table 165. Novartis Business Overview Table 166. Novartis Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Novartis Metoclopramide Product Portfolio Table 168. Novartis Recent Development Table 169. Johnson and Johnson Company Information Table 170. Johnson and Johnson Business Overview Table 171. Johnson and Johnson Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Johnson and Johnson Metoclopramide Product Portfolio Table 173. Johnson and Johnson Recent Development Table 174. Sanofi Company Information Table 175. Sanofi Business Overview Table 176. Sanofi Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Sanofi Metoclopramide Product Portfolio Table 178. Sanofi Recent Development Table 179. Teva Company Information Table 180. Teva Business Overview Table 181. Teva Metoclopramide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Teva Metoclopramide Product Portfolio Table 183. Teva Recent Development Table 184. Key Raw Materials Table 185. Raw Materials Key Suppliers Table 186. Metoclopramide Distributors List Table 187. Metoclopramide Customers List Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources Table 191. Primary Sources List of Figures Figure 1. Metoclopramide Product Image Figure 2. Global Metoclopramide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metoclopramide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metoclopramide Sales (2021-2032) & (K Units) Figure 5. Global Metoclopramide Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Metoclopramide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. Global Metoclopramide Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Metoclopramide Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Metoclopramide Sales Volume Share by Type (2021-2032) Figure 14. Global Metoclopramide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Metoclopramide Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Metoclopramide Sales Value Share by Type (2021-2032) Figure 17. Nausea Image Figure 18. Migraine Image Figure 19. Gastroparesis Image Figure 20. Global Metoclopramide Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Metoclopramide Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Metoclopramide Sales Volume Share by Application (2021-2032) Figure 23. Global Metoclopramide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Metoclopramide Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Metoclopramide Sales Value Share by Application (2021-2032) Figure 26. Global Metoclopramide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Metoclopramide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Metoclopramide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Metoclopramide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Metoclopramide Sales Value (2021-2032) & (US$ Million) Figure 31. North America Metoclopramide Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Metoclopramide Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Metoclopramide Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Metoclopramide Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Metoclopramide Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Metoclopramide Sales Value (2021-2032) & (US$ Million) Figure 37. South America Metoclopramide Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Metoclopramide Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Metoclopramide Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Metoclopramide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Metoclopramide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Metoclopramide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Metoclopramide Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Metoclopramide Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Nausea
  • Migraine
  • Gastroparesis
Companies covered
  • Adwya
  • Alkaloid Pharmaceuticals
  • Amneal Pharmaceuticals
  • Apotex
  • ASKA Seiyaku Asuka
  • Astellas
  • Biofarma
  • Ceva Sante Animale
  • EU-Pharma
  • Le Vet
  • Meda Pharma
  • Nidda
  • Omega Laboratories
  • Orion Pharma
  • Teuto Brasileiro
  • Wockhardt
  • Yang Sheng
  • GSK
  • Pfizer
  • Mylan
  • Novartis
  • Johnson and Johnson
  • Sanofi
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metoclopramide Sales Value (2021-2032)
  4. 1.2.2 Global Metoclopramide Sales Volume (2021-2032)
  5. 1.2.3 Global Metoclopramide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metoclopramide Market Dynamics
  1. 2.1 Metoclopramide Industry Trends
  2. 2.2 Metoclopramide Industry Drivers
  3. 2.3 Metoclopramide Industry Opportunities and Challenges
  4. 2.4 Metoclopramide Industry Restraints
3 Metoclopramide Market by Company
  1. 3.1 Global Metoclopramide Company Revenue Ranking in 2025
  2. 3.2 Global Metoclopramide Revenue by Company (2021-2026)
  3. 3.3 Global Metoclopramide Sales Volume by Company (2021-2026)
  4. 3.4 Global Metoclopramide Average Price by Company (2021-2026)
  5. 3.5 Global Metoclopramide Company Ranking (2024-2026)
  6. 3.6 Global Metoclopramide Company Manufacturing Base and Headquarters
  7. 3.7 Global Metoclopramide Company Product Type and Application
  8. 3.8 Global Metoclopramide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metoclopramide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metoclopramide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metoclopramide Market by Type
  1. 4.1 Metoclopramide Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Metoclopramide Sales Volume by Type
  5. 4.2.1 Global Metoclopramide Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Metoclopramide Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Metoclopramide Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Metoclopramide Sales Value by Type
  9. 4.3.1 Global Metoclopramide Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Metoclopramide Sales Value by Type (2021-2032)
  11. 4.3.3 Global Metoclopramide Sales Value Share by Type (2021-2032)
5 Metoclopramide Market by Application
  1. 5.1 Metoclopramide Application Introduction
  2. 5.1.1 Nausea
  3. 5.1.2 Migraine
  4. 5.1.3 Gastroparesis
  5. 5.2 Global Metoclopramide Sales Volume by Application
  6. 5.2.1 Global Metoclopramide Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metoclopramide Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Metoclopramide Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Metoclopramide Sales Value by Application
  10. 5.3.1 Global Metoclopramide Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metoclopramide Sales Value by Application (2021-2032)
  12. 5.3.3 Global Metoclopramide Sales Value Share by Application (2021-2032)
6 Metoclopramide Regional Sales and Value Analysis
  1. 6.1 Global Metoclopramide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metoclopramide Sales by Region (2021-2032)
  3. 6.2.1 Global Metoclopramide Sales by Region: 2021-2026
  4. 6.2.2 Global Metoclopramide Sales by Region (2027-2032)
  5. 6.3 Global Metoclopramide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metoclopramide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metoclopramide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metoclopramide Sales Value by Region (2027-2032)
  9. 6.5 Global Metoclopramide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metoclopramide Sales Value (2021-2032)
  12. 6.6.2 North America Metoclopramide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metoclopramide Sales Value (2021-2032)
  15. 6.7.2 Europe Metoclopramide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metoclopramide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metoclopramide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metoclopramide Sales Value (2021-2032)
  21. 6.9.2 South America Metoclopramide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metoclopramide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metoclopramide Sales Value Share by Country, 2025 VS 2032
7 Metoclopramide Country-level Sales and Value Analysis
  1. 7.1 Global Metoclopramide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metoclopramide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metoclopramide Sales by Country (2021-2032)
  4. 7.3.1 Global Metoclopramide Sales by Country (2021-2026)
  5. 7.3.2 Global Metoclopramide Sales by Country (2027-2032)
  6. 7.4 Global Metoclopramide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metoclopramide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metoclopramide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metoclopramide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metoclopramide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metoclopramide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metoclopramide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metoclopramide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metoclopramide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metoclopramide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metoclopramide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metoclopramide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metoclopramide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metoclopramide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metoclopramide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metoclopramide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metoclopramide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metoclopramide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metoclopramide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metoclopramide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metoclopramide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metoclopramide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metoclopramide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metoclopramide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metoclopramide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metoclopramide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metoclopramide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metoclopramide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metoclopramide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metoclopramide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metoclopramide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metoclopramide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metoclopramide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metoclopramide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metoclopramide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metoclopramide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metoclopramide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metoclopramide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metoclopramide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metoclopramide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metoclopramide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metoclopramide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metoclopramide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metoclopramide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metoclopramide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metoclopramide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metoclopramide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metoclopramide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metoclopramide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metoclopramide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metoclopramide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metoclopramide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metoclopramide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metoclopramide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metoclopramide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metoclopramide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metoclopramide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metoclopramide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metoclopramide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metoclopramide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metoclopramide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metoclopramide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metoclopramide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metoclopramide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metoclopramide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metoclopramide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metoclopramide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metoclopramide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metoclopramide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metoclopramide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metoclopramide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metoclopramide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metoclopramide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metoclopramide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metoclopramide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metoclopramide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metoclopramide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metoclopramide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metoclopramide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metoclopramide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metoclopramide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metoclopramide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metoclopramide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metoclopramide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metoclopramide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metoclopramide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metoclopramide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Adwya
  2. 8.1.1 Adwya Company Information
  3. 8.1.2 Adwya Business Overview
  4. 8.1.3 Adwya Metoclopramide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Adwya Metoclopramide Product Portfolio
  6. 8.1.5 Adwya Recent Developments
  7. 8.2 Alkaloid Pharmaceuticals
  8. 8.2.1 Alkaloid Pharmaceuticals Company Information
  9. 8.2.2 Alkaloid Pharmaceuticals Business Overview
  10. 8.2.3 Alkaloid Pharmaceuticals Metoclopramide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Alkaloid Pharmaceuticals Metoclopramide Product Portfolio
  12. 8.2.5 Alkaloid Pharmaceuticals Recent Developments
  13. 8.3 Amneal Pharmaceuticals
  14. 8.3.1 Amneal Pharmaceuticals Company Information
  15. 8.3.2 Amneal Pharmaceuticals Business Overview
  16. 8.3.3 Amneal Pharmaceuticals Metoclopramide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amneal Pharmaceuticals Metoclopramide Product Portfolio
  18. 8.3.5 Amneal Pharmaceuticals Recent Developments
  19. 8.4 Apotex
  20. 8.4.1 Apotex Company Information
  21. 8.4.2 Apotex Business Overview
  22. 8.4.3 Apotex Metoclopramide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Apotex Metoclopramide Product Portfolio
  24. 8.4.5 Apotex Recent Developments
  25. 8.5 ASKA Seiyaku Asuka
  26. 8.5.1 ASKA Seiyaku Asuka Company Information
  27. 8.5.2 ASKA Seiyaku Asuka Business Overview
  28. 8.5.3 ASKA Seiyaku Asuka Metoclopramide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ASKA Seiyaku Asuka Metoclopramide Product Portfolio
  30. 8.5.5 ASKA Seiyaku Asuka Recent Developments
  31. 8.6 Astellas
  32. 8.6.1 Astellas Company Information
  33. 8.6.2 Astellas Business Overview
  34. 8.6.3 Astellas Metoclopramide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Astellas Metoclopramide Product Portfolio
  36. 8.6.5 Astellas Recent Developments
  37. 8.7 Biofarma
  38. 8.7.1 Biofarma Company Information
  39. 8.7.2 Biofarma Business Overview
  40. 8.7.3 Biofarma Metoclopramide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biofarma Metoclopramide Product Portfolio
  42. 8.7.5 Biofarma Recent Developments
  43. 8.8 Ceva Sante Animale
  44. 8.8.1 Ceva Sante Animale Company Information
  45. 8.8.2 Ceva Sante Animale Business Overview
  46. 8.8.3 Ceva Sante Animale Metoclopramide Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Ceva Sante Animale Metoclopramide Product Portfolio
  48. 8.8.5 Ceva Sante Animale Recent Developments
  49. 8.9 EU-Pharma
  50. 8.9.1 EU-Pharma Company Information
  51. 8.9.2 EU-Pharma Business Overview
  52. 8.9.3 EU-Pharma Metoclopramide Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 EU-Pharma Metoclopramide Product Portfolio
  54. 8.9.5 EU-Pharma Recent Developments
  55. 8.10 Le Vet
  56. 8.10.1 Le Vet Company Information
  57. 8.10.2 Le Vet Business Overview
  58. 8.10.3 Le Vet Metoclopramide Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Le Vet Metoclopramide Product Portfolio
  60. 8.10.5 Le Vet Recent Developments
  61. 8.11 Meda Pharma
  62. 8.11.1 Meda Pharma Company Information
  63. 8.11.2 Meda Pharma Business Overview
  64. 8.11.3 Meda Pharma Metoclopramide Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Meda Pharma Metoclopramide Product Portfolio
  66. 8.11.5 Meda Pharma Recent Developments
  67. 8.12 Nidda
  68. 8.12.1 Nidda Company Information
  69. 8.12.2 Nidda Business Overview
  70. 8.12.3 Nidda Metoclopramide Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Nidda Metoclopramide Product Portfolio
  72. 8.12.5 Nidda Recent Developments
  73. 8.13 Omega Laboratories
  74. 8.13.1 Omega Laboratories Company Information
  75. 8.13.2 Omega Laboratories Business Overview
  76. 8.13.3 Omega Laboratories Metoclopramide Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Omega Laboratories Metoclopramide Product Portfolio
  78. 8.13.5 Omega Laboratories Recent Developments
  79. 8.14 Orion Pharma
  80. 8.14.1 Orion Pharma Company Information
  81. 8.14.2 Orion Pharma Business Overview
  82. 8.14.3 Orion Pharma Metoclopramide Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Orion Pharma Metoclopramide Product Portfolio
  84. 8.14.5 Orion Pharma Recent Developments
  85. 8.15 Teuto Brasileiro
  86. 8.15.1 Teuto Brasileiro Company Information
  87. 8.15.2 Teuto Brasileiro Business Overview
  88. 8.15.3 Teuto Brasileiro Metoclopramide Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Teuto Brasileiro Metoclopramide Product Portfolio
  90. 8.15.5 Teuto Brasileiro Recent Developments
  91. 8.16 Wockhardt
  92. 8.16.1 Wockhardt Company Information
  93. 8.16.2 Wockhardt Business Overview
  94. 8.16.3 Wockhardt Metoclopramide Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Wockhardt Metoclopramide Product Portfolio
  96. 8.16.5 Wockhardt Recent Developments
  97. 8.17 Yang Sheng
  98. 8.17.1 Yang Sheng Company Information
  99. 8.17.2 Yang Sheng Business Overview
  100. 8.17.3 Yang Sheng Metoclopramide Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Yang Sheng Metoclopramide Product Portfolio
  102. 8.17.5 Yang Sheng Recent Developments
  103. 8.18 GSK
  104. 8.18.1 GSK Company Information
  105. 8.18.2 GSK Business Overview
  106. 8.18.3 GSK Metoclopramide Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 GSK Metoclopramide Product Portfolio
  108. 8.18.5 GSK Recent Developments
  109. 8.19 Pfizer
  110. 8.19.1 Pfizer Company Information
  111. 8.19.2 Pfizer Business Overview
  112. 8.19.3 Pfizer Metoclopramide Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Pfizer Metoclopramide Product Portfolio
  114. 8.19.5 Pfizer Recent Developments
  115. 8.20 Mylan
  116. 8.20.1 Mylan Company Information
  117. 8.20.2 Mylan Business Overview
  118. 8.20.3 Mylan Metoclopramide Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Mylan Metoclopramide Product Portfolio
  120. 8.20.5 Mylan Recent Developments
  121. 8.21 Novartis
  122. 8.21.1 Novartis Company Information
  123. 8.21.2 Novartis Business Overview
  124. 8.21.3 Novartis Metoclopramide Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Novartis Metoclopramide Product Portfolio
  126. 8.21.5 Novartis Recent Developments
  127. 8.22 Johnson and Johnson
  128. 8.22.1 Johnson and Johnson Company Information
  129. 8.22.2 Johnson and Johnson Business Overview
  130. 8.22.3 Johnson and Johnson Metoclopramide Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Johnson and Johnson Metoclopramide Product Portfolio
  132. 8.22.5 Johnson and Johnson Recent Developments
  133. 8.23 Sanofi
  134. 8.23.1 Sanofi Company Information
  135. 8.23.2 Sanofi Business Overview
  136. 8.23.3 Sanofi Metoclopramide Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Sanofi Metoclopramide Product Portfolio
  138. 8.23.5 Sanofi Recent Developments
  139. 8.24 Teva
  140. 8.24.1 Teva Company Information
  141. 8.24.2 Teva Business Overview
  142. 8.24.3 Teva Metoclopramide Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Teva Metoclopramide Product Portfolio
  144. 8.24.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metoclopramide Value Chain Analysis
  2. 9.1.1 Metoclopramide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metoclopramide Sales Mode & Process
  6. 9.2 Metoclopramide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metoclopramide Distributors
  9. 9.2.3 Metoclopramide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst